Australia's most trusted
source of pharma news
Friday, 23 January 2026
Posted 22 January 2026 PM
Eli Lilly has officially resolved a three-and-a-half-year shortage of Trulicity, overcoming manufacturing issues plus the huge knock-on effect from a spike in demand for a rival drug, Novo Nordisk's Ozempic.
Extensive off-label prescribing of Ozempic for weight loss had a domino effect on the supply of Trulicity, a weekly GLP-1 injectable, worldwide.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.